Biocon Limited has released its audited financial results for the quarter and year ended March 31, 2026. The Board approved the integration of its material subsidiary, Biocon Biologics Limited (BBL), as a wholly-owned entity. Key highlights include a final dividend of 10% (Re. 0.50 per share), a leadership expansion with new senior personnel, and significant structural changes including the appointment of a new Statutory Auditor and several key board appointments.
Financial Highlights and Dividend
For the financial year ended March 31, 2026, Biocon has reported audited financial results in line with Indian Accounting Standards. Reflecting on the company’s performance, the Board of Directors has recommended a final dividend of 10%, amounting to Re. 0.50 per equity share with a face value of Rs. 5 each. The record date for this dividend is fixed for July 3, 2026, with payment scheduled on or before August 31, 2026, subject to shareholder approval at the upcoming Annual General Meeting.
Strategic Integration and Acquisition
The company is finalizing the full integration of its subsidiary, Biocon Biologics Limited (BBL), to create a Unified Global Biopharmaceutical Leader. This strategic move includes acquiring the remaining ~2% of BBL’s paid-up equity share capital. The acquisition involves a preferential issue of 87,92,317 equity shares of Biocon, valued at an issue price of Rs. 376.16 per share, aggregating to approximately Rs. 330.73 Crores. Additionally, the Board approved the conversion of existing debentures (OCDs and CCDs) into 4,11,11,689 and 1,06,86,044 equity shares of BBL, respectively.
Leadership and Governance Changes
Biocon has significantly bolstered its leadership and governance structure. Dr. Anuj Goel and Mr. Susheel Umesh have been designated as Senior Management Personnel. Regarding the Board, Ms. Rekha Mehrotra Menon has been re-appointed as an Independent Director for a second 5-year term. Furthermore, in view of the integration with BBL, several industry veterans have been recommended for appointment as Independent Directors, including Mr. Rajiv Malik, Mr. Daniel Bradbury, Mr. Peter Baron Piot, Mr. Arun Suresh Chandavarkar, and Ms. Nivruti Rai, effective August 1, 2026.
Statutory Auditor Transition
The Board has recommended the appointment of M/s. S. R. Batliboi & Associates LLP as the new Statutory Auditors of the Company for a term of 5 consecutive years, starting from the conclusion of the 48th AGM until the conclusion of the 53rd AGM in 2031, replacing the retiring auditors, M/s. B S R & Co. LLP.
Employee Incentives
The company also introduced the Biocon Unity Long Term Incentive Plan 2026. This initiative includes various stock option and performance unit plans designed to incentivize eligible employees across the company and its subsidiaries, reinforcing the organization’s commitment to talent development and long-term value creation.
Source: BSE
